Neogenomics stock price target raised to $14 from $8 at Needham after patent win

Neogenomics (NEO) saw its price target raised to $14.00 by Needham, which maintained a Buy rating, following a pivotal patent infringement victory against Natera. This legal win enables NEO to fully commercialize its RaDaR ST assay, which Needham views as a significant long-term growth driver in the multi-billion dollar minimal residual disease (MRD) testing market, a development that has already spurred a positive market reaction. However, this positive momentum comes amidst recent downgrades from other firms like BTIG and William Blair, citing prior concerns over management credibility and missed Q2 earnings, underscoring a mixed outlook despite the legal win.

Analysis

Neogenomics (NEO) has secured a significant legal and commercial victory with a favorable summary judgment in its patent infringement case against Natera. The court's decision, which invalidates all of Natera's asserted claims and dismisses the case with prejudice, removes a major overhang and grants NEO the freedom to commercialize its RaDaR ST assay for minimal residual disease (MRD) testing. This development is the primary driver behind Needham's upgraded price target to $14.00 from $8.00 and has fueled a 9.16% stock return over the past week. Needham identifies RaDaR as a key long-term growth driver, citing the multi-billion dollar total available market for MRD. However, this positive catalyst is contrasted by recent operational challenges and eroded market confidence. Both BTIG and William Blair recently downgraded the stock, to Neutral and Market Perform respectively, citing concerns over management credibility and the time required to rebuild investor trust. These concerns are rooted in the company's second-quarter results, which missed revenue and EBITDA expectations and led to a downward revision of full-year 2025 guidance, despite a slight beat on EPS. The situation presents a clear dichotomy: a powerful, forward-looking growth story unlocked by the legal win versus a recent history of underperformance that has made some analysts cautious.

Key Decisions for Investors

• Investors should weigh the significant long-term growth potential unlocked by the commercialization of the RaDaR ST assay against the execution risks highlighted by recent downgrades and missed Q2 financial targets.
• Monitor management's commentary and execution on the RaDaR commercialization plan, as success here could validate Needham's bullish $14 price target and begin to rebuild credibility.
• Pay close attention to the third-quarter 2025 earnings call on November 11, as it is a key upcoming catalyst where management is expected to detail its broader RaDaR strategy and provide updated guidance.